Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 3;24(12):77.
doi: 10.1007/s11916-020-00911-6.

Latest Insights into the Pathophysiology of Migraine: the ATP-Sensitive Potassium Channels

Lili Kokoti  1 , Mohammad Al-Mahdi Al-Karagholi  1 , Messoud Ashina  2   3
Affiliations
Review

Latest Insights into the Pathophysiology of Migraine: the ATP-Sensitive Potassium Channels

Lili Kokoti et al. Curr Pain Headache Rep. .

Abstract

Purpose of review: Migraine remains a challenging condition to treat, thus highlighting the need for a better understanding of its molecular mechanisms. This review intends to unravel a new emerging target in migraine pathophysiology, the adenosine 5'-triphosphate-sensitive K+ (KATP) channel.

Recent findings: KATP channel is a common denominator in the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) mediated intracellular cascades, both of which are involved in migraine. Intravenous infusion of KATP channel opener, levcromakalim, provoked migraine attack associated with dilation of extracerebral arteries in all persons with migraine. Preclinical and clinical studies implicate KATP channels in migraine initiation. KATP channel is a novel therapeutic target for the acute and preventive treatment of migraine. Future studies are warranted to provide a better understanding of the role of KATP channel subgroups in migraine.

Keywords: Cromakalim; Headache; Human models; KATP channel; Migraine.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Clemente Agostoni E, Barbanti P, Calabresi P, The Italian chronic migraine group, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20. https://doi.org/10.1186/s10194-019-1038-4 .
    1. Goadsby PJ, Holland PR. Migraine therapy: current approaches and new horizons. Neurotherapeutics. 2018;15:271–3. - PubMed - PMC
    1. Bohm PE, Stancampiano FF, Rozen TD. Migraine headache: updates and future developments. Mayo Clin Proc. 2018;93:1648–53. - PubMed
    1. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394:1765–74. - PubMed
    1. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17:174–82. - PubMed

MeSH terms

LinkOut - more resources